Celsion Corp. (CLSN)
()
 
 

Overview

Founded in 1982, with a vision of using heat to kill cancer and treat other diseases, Celsion began trading publicly in 1985 under the name Cheung Laboratories, Inc. The early research focus of the company was device-oriented heat-based treatment systems. In the mid-1990s, Celsion focused its efforts on expanding the Company's research portfolio and licensed a technology for the treatment of Benign Prostatic Hyperplasia (BPH), and a heat activated liposomal drug delivery system. The company was renamed Celsion Corporation and listed on the American Stock Exchange under the symbol CLN, in 2000. In 2001, Celsion determined that its heat-activated liposomal drug delivery system presented the greatest potential for creation of long-term shareholder value and redirected its strategy to transition out of device development in order to focus exclusively on drug development.

Since 2001, Celsion ...


Contact Information

10220-l Old Columbia Road
Columbia, MD 21046

tel: 410-290-5390
fax: 410-290-5394
http://www.celsion.com

,  



Investor Relations

The Trout Group LLC
Marcy Nanus, Senior Associate
tel: 646 378 2927
fax: 646 378 2901
e-mail: mnanus@troutgroup.com




Stock

Exchange: NYSE
Industry: Pharmaceutical And Medicine Manufacturing
Market Cap: $41.4M




 
The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.